Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $86.49 | 10 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $41.09 | 3 | $0 (2022) |
| Genentech USA, Inc. | $32.86 | 6 | $0 (2021) |
| Lilly USA, LLC | $12.54 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $16.41 | 1 | ABBVIE INC. ($16.41) |
| 2021 | $70.08 | 9 | Genentech USA, Inc. ($32.86) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/03/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $16.41 | General |
| Category: NEUROSCIENCE | ||||||
| 12/16/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $2.46 | General |
| Category: Virology & Specialty Care | ||||||
| 12/08/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $9.28 | General |
| Category: Virology & Specialty Care | ||||||
| 10/15/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.21 | General |
| Category: NEUROSCIENCE | ||||||
| 09/28/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $7.31 | General |
| Category: Virology & Specialty Care | ||||||
| 06/10/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.47 | General |
| Category: NEUROSCIENCE | ||||||
| 02/25/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $4.45 | General |
| Category: Virology & Specialty Care | ||||||
| 02/17/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $6.00 | General |
| Category: Virology & Specialty Care | ||||||
| 01/28/2021 | Lilly USA, LLC | EMGALITY (Drug), REYVOW | Food and Beverage | In-kind items and services | $12.54 | General |
| Category: Neuroscience | ||||||
| 01/15/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $3.36 | General |
| Category: Virology & Specialty Care | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 66 | 93 | $4,953 | $1,987 |
| 2022 | 5 | 130 | 172 | $24,778 | $6,588 |
| 2021 | 11 | 389 | 677 | $115,619 | $21,523 |
| 2020 | 9 | 287 | 341 | $42,808 | $14,971 |
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 25 | 26 | $2,288 | $900.12 | 39.3% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 26 | 52 | $2,050 | $843.44 | 41.1% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2023 | 15 | 15 | $615.00 | $243.00 | 39.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 24 | 27 | $9,612 | $2,194 | 22.8% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 50 | 58 | $5,617 | $2,024 | 36.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $7,311 | $1,475 | 20.2% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 26 | 52 | $2,018 | $846.74 | 42.0% |
| 81003 | Automated urinalysis test | Office | 2022 | 17 | 22 | $220.00 | $48.93 | 22.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 69 | 92 | $40,572 | $7,986 | 19.7% |
| 87428 | Sarscov & inf vir a&b ag ia | Office | 2021 | 73 | 81 | $23,490 | $5,151 | 21.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 32 | 32 | $21,344 | $3,525 | 16.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 34 | 37 | $11,137 | $1,847 | 16.6% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 20 | 20 | $8,800 | $1,471 | 16.7% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 51 | 78 | $5,304 | $651.01 | 12.3% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Office | 2021 | 11 | 11 | $3,410 | $644.71 | 18.9% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2021 | 31 | 36 | $936.00 | $153.37 | 16.4% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2021 | 19 | 96 | $288.00 | $37.74 | 13.1% |
| 81003 | Automated urinalysis test | Office | 2021 | 14 | 16 | $160.00 | $36.00 | 22.5% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2021 | 35 | 178 | $178.00 | $21.20 | 11.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 105 | 135 | $24,655 | $6,965 | 28.2% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2020 | 21 | 21 | $4,935 | $2,941 | 59.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 73 | 87 | $8,533 | $2,784 | 32.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 15 | 15 | $2,400 | $1,416 | 59.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 11 | 12 | $444.00 | $324.28 | 73.0% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 17 | 17 | $356.00 | $186.67 | 52.4% |
About Shawna Mathis
Shawna Mathis is a Family healthcare provider based in Clarksville, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/08/2016. The National Provider Identifier (NPI) number assigned to this provider is 1538603600.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Shawna Mathis has received a total of $86.49 in payments from pharmaceutical and medical device companies, with $16.41 received in 2022. These payments were reported across 10 transactions from 3 companies. The most common payment nature is "Food and Beverage" ($86.49).
As a Medicare-enrolled provider, Mathis has provided services to 872 Medicare beneficiaries, totaling 1,283 services with total Medicare billing of $45,070. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Practice Information
- Specialty Family
- Location Clarksville, IN
- Active Since 12/08/2016
- Last Updated 02/19/2024
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1538603600
Products in Payments
- Xofluza (Drug) $32.86
- VRAYLAR (Drug) $24.68
- UBRELVY (Drug) $16.41
- EMGALITY (Drug) $12.54
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Clarksville
Rhonda Hettinger, Np, NP
Family — Payments: $35,080
Kayla Teives, Np-C, NP-C
Family — Payments: $8,369
Danielle Conroy, Np, NP
Family — Payments: $5,696
Mrs. Terry Holt, Fnp, FNP
Family — Payments: $4,648
Mrs. Carrie Hinton, Aprn, Fnp-C, APRN, FNP-C
Family — Payments: $4,601
Charlsie Deloach, Fnp-Cb, FNP-CB
Family — Payments: $4,589